Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Human CD123 Monoclonal Antibody□N297Q)

Catalog No.: YR0503

Basic Information

Molecular Weight
150 kDa

Endotoxin
<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay

Sterility
0.2 μm filtration

Aggregation
<5% Determined by SECP

Purity
>95% Determined by SDS-PAGE

Background

Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Reported Applications

ELISA,neutralization,functional assays such as bioanalytical P K and ADA assays,and those assays for studying biological pathways

Immunogen Information

Clone
Pivekimab Biosimilar

Isotype
Human IgG1 kappa

Immunogen

RecommendedIsotype Control(s)

Recommended Dilution Buffer
1×PBS pH 7.3

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn


Product Information

Production
Purified from cell culture supernatant in an animal-free facility


Purification
Protein A or G purification

Storage
Store at -20℃

Validation Data



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD123 (Research Grade Pivekimab (N297Q) Biosimilar) Monoclonal Antibody to CD123. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human CD123 SPR assay. Determined through SPR assay, the Human Anti-Human CD123 (Research Grade Pivekimab (N297Q) Biosimilar) Monoclonal Antibody is Capable of binding to Human Trop-2with an affinity constant of 29.26pM.